Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 193Neoplasm Metastasis 22Prostatic Neoplasms, Castration-Resistant 20Breast Neoplasms 19Neoplasms 17Metastatic Castration Resistant Prostate Cancer 10Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Triple Negative Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Neoplasms 5Castration-resistant Prostate Cancer 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Colorectal Neoplasms 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Prostate Adenocarcinoma 3Ovarian Neoplasms 3Carcinoma, Hepatocellular 3mCRPC 2Uterine Cervical Neoplasms 2Recurrence 2Prostatic Diseases 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Hormone-sensitive Prostate Cancer 2

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × enzalutamide × Clear all
NCT03460977 2026-05-20

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT06551324 2026-05-05

MEVPRO-1

Pfizer

Phase 3 Active not recruiting
600 enrolled
Genitourinary

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡